Yazar "Ozmen, Tolga" için listeleme
-
Comparison of breast cancer patients who underwent partial mastectomy (PM) with mini latissimus dorsi flap (MLDF) and subcutaneous mastectomy with implant (M plus I) regarding quality of life (QOL), cosmetic outcome and survival rates
Ozmen, Vahit; Ilgun, Serkan; Ozden, Burcu Celet; Ozturk, Alper; Aktepe, Fatma; Agacayak, Filiz; Ozmen, Tolga (Bmc, 2020)Purpose the latissimus dorsi muscle has long been used in breast cancer (BC) patients for reconstruction. This study aimed to compare early stage BC patients who had partial mastectomy (PM) with mini latissimus dorsi flap ... -
Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study
Unal, Caglar; Ordu, Cetin; Ozmen, Tolga; Ilgun, Ahmet Serkan; Celebi, Filiz; Baysal, Buelent; Ozkurt, Enver (Mdpi, 2023)Estradiol (E2), a follicle-stimulating hormone (FSH), AMH, and inhibin B levels, along with AFC and MOV, are used to determine ovarian reserve in pre-menopausal women. Studies have shown that AMH levels are more sensitive ... -
MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification
Unal, Caglar; Ozmen, Tolga; Ilgun, Ahmet Serkan; Ordu, Cetin; Ozkurt, Enver; Ak, Naziye; Alco, Gul (Dove Medical Press Ltd, 2023)Background: The minichromosome maintenance protein-2 (MCM-2) is a more sensitive proliferation marker than Ki-67. This study aimed to evaluate the relationship between MCM-2 and Oncotype DX recurrence score (ODX-RS) and ... -
Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
Unal, Caglar; Ozmen, Tolga; Ordu, Cetin; Pilanci, Kezban Nur; Ilgun, Ahmet Serkan; Gokmen, Erhan; Almuradova, Elvina (Frontiers Media Sa, 2023)Background: The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant chemotherapy decision-making process for patients with early-stage hormone receptor-positive, HER-2 receptor-negative breast cancer. This study aimed ...